本文選題：華法林抗凝 + 國際標(biāo)準(zhǔn)化比值　； 參考：《重慶醫(yī)學(xué)》2014年27期

【摘要】：正肺動(dòng)脈栓塞(pulmonary embolism,PE)是由于內(nèi)源性或外源性栓子,堵塞肺動(dòng)脈或其分支而引起肺循環(huán)障礙的臨床和病理生理綜合征,是心血管急癥,其病死率僅次于惡性腫瘤和心肌梗死。研究表明,40%~60%PE與肢體靜脈血栓形成有關(guān),其主要原因?yàn)橹w或盆腔靜脈血栓形成后脫落所致[1]�？鼓委熓荘E標(biāo)準(zhǔn)治療的重要組成部分,根據(jù)指南使用華法林抗凝,由于諸多因素影響,使得華法林劑量存在明顯個(gè)體化差
[Abstract]:Pulmonary embolism (PE) is a kind of clinical and pathophysiological syndrome, which is caused by endogenous or exogenous embolism, blockage of pulmonary artery or its branches. It is a cardiovascular emergency, and its mortality is second only to malignant tumor and myocardial infarction.The results showed that the main cause of venous thrombosis was the shedding of venous thrombosis in the extremity or pelvic vein [1].Anticoagulant therapy is an important part of PE standard therapy. Warfarin anticoagulant is used according to the guidelines. Because of many factors, warfarin dosage is obviously different.
【作者單位】： 達(dá)州市中心醫(yī)院藥學(xué)部;
【分類號(hào)】：R563.5
，

本文編號(hào)：1772085